Israeli Scientists finds a lasting cure to Cancer

A team of scientist at the  Accelerated Evolution Biotechnologies Ltd Isreal (AEBi) claim they have found a lasting cure to cancer.

Dan Aridor the Chairman of the Board of AEBi speaking about the miracle cancer drug said.

“We believe we will offer in a year’s time a complete cure for cancer,”

“Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market,”

“Our solution will be both generic and personal.”

MuTaTo or multi-target toxin which is the name of the cancer drug acts as a “cancer antibiotic” and uses a combination of cancer-targeting peptides (amino acid chains) and a toxin that specifically kills cancer cells.

These scientists have studied why previous drugs designed to annihilate cancer failed.

They found out that one of the reasons is that cancer drugs attack a specific target in or on one cancer cells at a time. Mutations that occur in cancer cells also make the anti-cancer drugs ineffective.

However, in the case of MuTaTo, it uses several cancer-targeting peptides on a single cancer cell all at once, along with a cancer-destroying toxin.

Dr. Ilan Morad the CEO of AEBi said by using MuTaTo,

“we made sure that the treatment will not be affected by mutations; cancer cells can mutate in such a way that targeted receptors are dropped by cancer.”

“The probability of having multiple mutations that would modify all targeted receptors simultaneously decreases dramatically with the number of targets used,” Morad continued.

“Instead of attacking receptors one at a time, we attack receptors three at a time – not even cancer can mutate three receptors at the same time.”

Another reason they found out that made previous cancer drugs to fail is that the drugs do not destroy the cancer stem cells. This problem alone may cause cancer to return even after treatment.

Dr. Ilan Morad speaking about that said

“If it does not completely annihilate cancer, the remaining cells can start to get mutations again, and then cancer comes back, but this time it is drug resistant,”

and in the case of MuTaTo, it is small, flexible and strong enough to both destroy the cancer stem cells and penetrate where other drugs cannot reach.

“This should make the whole molecule non-immunogenic in most cases and would enable repeated administration of the drug,” Morad said.

He further added that MuTaTo will dramatically decree the side effect of tanking anti-cancer drugs because of the
drug does not target non-cancerous cells.

Current cancer drugs can destroy both cancer cells and non-cancer cells, thereby creating a severe side effect in some cases.

MuTaTo can also be personalized once the cancer patient can provide the lab with his or her biopsy. The scientist will analyze it and provide the patient with a personalized version of the drug the will specifically destroy their particular cancer.

AEBi will soon move to clinical trials of the drug but have tested it on mice and will make the treatment available in few years.

If the drug is successful, it has the potential of revolutionalising cancer treatments globally and giving hope to millions of people diagnosed with the disease every year.